Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of the predictive role of 5-HTTLPR polymorphism on escitalopram response in obsessive-compulsive disorder
2009-016443-19Phase 4Active
- Sponsor
- CHU de Poitiers
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of escitalopram in obsessive compulsive disorder (OCD), sponsored by CHU de Poitiers. Primary endpoint: Treatment response to escitalopram at 12 weeks. Started Nov 2009; status: active.
02
Drugs
escitalopram
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on 2009-016443-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016443-19.